Picolinic acid- or desferrioxamine-inducible autocrine activation of macrophages engineered to produce IFNgamma: an approach for gene therapy.
D000818:Animals; D019898:Autocrine Communication; D002460:Cell Line; D003676:Deferoxamine / Q000494:pharmacology*; D004357:Drug Synergism; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000276:immunology*; D007371:Interferon-gamma / Q000276:immunology; D007501:Iron / Q000494:pharmacology; D007502:Iron Chelating Agents / Q000494:pharmacology*; D008262:Macrophage Activation / Q000187:drug effects; D008264:Macrophages / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D019001:Nitric Oxide Synthase / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II; D010587:Phagocytosis; D010848:Picolinic Acids / Q000494:pharmacology*; D013268:Stimulation, Chemical; D014162:Transfection / Q000379:methods; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D007502:Iron Chelating Agents; D010848:Picolinic Acids; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma; D007501:Iron; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse; D003676:Deferoxamine; C030614:picolinic acid